In a significant development, the U.S. Food and Drug Administration (FDA) has issued Marketing Denial Orders (MDOs) for two products from Vuse, a brand owned by British American Tobacco (BAT). The affected products are the Vuse Vibe Tank Menthol 3.0% and the Vuse Ciro Cartridge Menthol 1.5%. This decision by the FDA is based on its assessment that the applications for these products did not provide sufficient evidence to justify their marketing under the legal standards mandated by the 2009 Family Smoking Prevention and Tobacco Control Act.
FDA’s Determination versus British American Tobacco
The FDA’s primary concern is the protection of public health, and any tobacco or nicotine-related product must meet stringent criteria to be deemed suitable for the market. In this case, the FDA determined that the applications for the Vuse Vibe Tank Menthol 3.0% and the Vuse Ciro Cartridge Menthol 1.5% fell short of providing the necessary evidence to support their marketing.
This decision has raised questions about the products’ safety and their potential impact on public health, particularly in relation to their use by adult smokers seeking alternatives to traditional cigarettes.
BAT’ Response to FDA
In response to the FDA’s decision, a spokesperson from British American Tobacco, the parent company of Reynolds, which owns the Vuse brand, expressed disappointment. The spokesperson stated, “We are disappointed in FDA’s decision to issue MDOs for two Vuse products—the Vuse Vibe Tank Menthol 3.0% and the Vuse Ciro Cartridge Menthol 1.5%. Reynolds intends to seek a stay of enforcement immediately and will pursue other appropriate avenues to allow Vuse to continue offering its innovative products to adult nicotine consumers age 21+ without interruption.”
The spokesperson further added, “We believe that menthol vapor products are critical to helping adult smokers migrate away from combustible cigarettes. FDA’s decision, if allowed to go into effect, will harm, not benefit, public health. Reynolds will challenge the denials.”
Menthol Vapor Products and Public Health
Menthol-flavored tobacco and nicotine products have long been a subject of debate, particularly in relation to other flavorings that often come under public and regulators’s scrutinity (such as fruit flavors). On one side, advocates argue that such products may serve as a less harmful alternative for adult smokers trying to quit traditional cigarettes. On the other, opponents express concerns that these flavors may appeal to youth and non-smokers, potentially leading to nicotine addiction.
The FDA’s decision to issue MDOs for the Vuse menthol products is in line with its commitment to rigorously evaluate the safety and public health impact of all tobacco and nicotine-related products. The agency’s decision reflects its judgment that the available evidence did not meet the necessary standards for marketing authorization.
What’s Next
The issuance of MDOs is not the end of the road for these products. British American Tobacco, through its subsidiary Reynolds, has indicated its intention to challenge these denials and seek ways to continue offering these menthol products to adult consumers. Legal and regulatory battles may ensue, as the company strives to demonstrate the safety and public health benefits of these products.
The outcome of these challenges will have broader implications for the regulation of flavored tobacco and nicotine products in the United States. The FDA’s decision sets a precedent for how such products are evaluated and authorized for the market, impacting both industry players and consumers.
As the situation unfolds, it remains a topic of significant interest to those in the tobacco and public health sectors, as well as adult consumers who use these products as an alternative to traditional cigarettes.
